A team of researchers from the University of Cologne's Faculty of Medicine and University Hospital Cologne, led by Dr. Yuri Tolkach and Professor Dr. Reinhard Büttner, has created a digital pathology ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance ...

The image shows how the algorithm processes the typically coloured tissue section (left) and creates a map in which different types of tissue can be seen in different colours (the algorithm identifies ...

Predictive implications of immune-related adverse events after exposure to VEGF inhibitors on outcomes in patients with advanced NSCLC treated with prior immune check point inhibitor. This is an ASCO ...

A team of researchers from the University of Cologne's Faculty of Medicine and University Hospital Cologne, led by Dr Yuri Tolkach and Professor Dr Reinhard Büttner, has created a digital pathology ...

Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience. Biomarker testing and targeted therapy use among patients with non-small cell ...

Lung adenocarcinoma is the most common type of lung cancer diagnosed in the U.S. Just over half of all non-small-cell lung cancers (NSCLCs) are adenocarcinomas. Finding out that you're at risk of lung ...

For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the ...